EYENOVIA INC. - COMMO

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

20 апр 2022 08:00:00 Источник Nasdaq GlobeNewswire

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

19 апр 2022 08:00:01 Источник Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

28 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28

21 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

15 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.

04 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

08 фев 2022 08:00:03 Источник Nasdaq GlobeNewswire

Eyenovia Announces Changes to Board of Directors

07 фев 2022 08:30:00 Источник Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2021 Financial Results

10 ноя 2021 16:05:02 Источник Nasdaq GlobeNewswire

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

08 ноя 2021 08:00:02 Источник Nasdaq GlobeNewswire

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

05 ноя 2021 15:25:02 Источник Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

04 ноя 2021 16:05:03 Источник Nasdaq GlobeNewswire

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

04 ноя 2021 08:00:02 Источник Nasdaq GlobeNewswire

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

25 окт 2021 08:00:01 Источник Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2021 Financial Results

11 авг 2021 16:05:00 Источник Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11

04 авг 2021 08:00:01 Источник Nasdaq GlobeNewswire

Eyenovia to Participate in Two Upcoming Investor Conferences

07 июл 2021 16:01:00 Источник Nasdaq GlobeNewswire

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

15 июн 2021 08:00:02 Источник Nasdaq GlobeNewswire

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

25 май 2021 09:03:54 Источник Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2021 Financial Results

12 май 2021 16:05:01 Источник Nasdaq GlobeNewswire